Teva Pharmaceutical and AbCellera have entered into a research colaboration under which AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.   AbCellera will receive an upfront payment, research payments, and is eligible to receive milestones associated with the development and approval of therapeutic antibodies.   “We are pleased to work with AbCellera utilizing this company’s novel biologics technology,” said Michael Hayden...